A new conceptual model provides a framework for early health technology assessment of tissue-engineered heart valves to guide development and reimbursement decisions.
May inform early TEHV development and reimbursement; leaves open real-world cost-effectiveness pending clinical data.
We developed a CM that will serve as foundation of a decision-analytic model that can estimate the potential cost-effectiveness of TEHV in early development stages. This supports developers in deciding about further development of TEHV and identifies promising interventions that may result in faster take-up in clinical practice by clinicians and reimbursement by payers.
No takes yet. Share an insight, caveat, or question.
Huygens et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: